대한뉴팜

- Sustained substantial qualitative growth (25.4% sales growth, 77.6% ordinary profit growth)- Entered the 10 billion KRW operating profit club (operating profit of 10.052 billion KRW)- Announced new management philosophy and vision Daehan New Pharm had a remarkable 2015. Total sales for 2015 reached 90.23 billion KRW, a 25.4% increase year-on-year. Operating profit rose 27.1% to 10.052 billion KRW, and ordinary profit surged 77.6% to 6.422 billion KRW, maintaining a high-growth trend fueled by continuous 20% growth and improved financial structure. Entering the 10 billion KRW operating profit club holds significant meaning. This growth reflects strategic innovation and relentless drive for evolution and development: Successful entry into the elderly chronic disease market through continuous new product launches and strategic focus, pursuing qualitative growth in generics. Strengthening of its well-being portfolio by diversifying functional health foods, cosmetics, and obesity products, enhancing its domestic leading position. Building a stable growth foundation through restructuring the animal medicine business and focusing on core product groups, bolstering growth potential with specialized bio-technology products aimed at the swine market. Opening of a bio R&D center in Osong Advanced Medical Complex conducting immune cell and stem cell research and enhancing efficiency through active industry-academia cooperation. Strengthening partnerships at overseas strategic bases such as Russia and expanding overseas business while well-being products influenced by Hallyu (Korean wave) have received positive feedback in China and Southeast Asia. As a result, Daehan New Pharm received the "$10 Million Export Tower" award at the 52nd Trade Day in December. At the end of the year, marking its 30th anniversary, Daehan New Pharm reestablished its management philosophy under "Daehan New Pharm sharing health, happiness, and warmth," based on human-centered, creative, and ethical management. It announced a new vision, "New Platform for Life Care," focusing on bio-business as a core, shared by all employees. In 2016, under the slogan "Smart Start for The Great DHNP," Daehan New Pharm will strengthen its sales responsibility system, activate HR and sales execution programs, and accelerate strategic innovation focusing on bio and overseas business as new growth engines to ensure a successful second leap.

On December 15, 2015, Daehan New Pharm signed an agreement with Professor Hwa-Young Yoon of the College of Veterinary Medicine at Seoul National University to conduct joint research and provide technical consultation for the industrialization of stem cells for companion animals. Going forward, both parties plan to develop stem cells that can be widely applied to intractable diseases such as spinal cord injuries, degenerative arthritis, autoimmune disorders, and chronic renal failure through innovations in stem cell culture technology and various clinical trials. The developed technology will first be applied in animal hospitals and later expanded to the development of stem cell therapies for human use. In addition, Daehan New Pharm plans to enhance its stem cell technologies currently under development and ownership to accelerate market entry, while also discussing potential export opportunities with overseas buyers in rapidly growing companion animal markets such as China and Vietnam, where economic growth and rising income levels are fueling expansion.

Daehan New Pharm, the recipient of the 10 Million Dollar Export Tower Award at the 52nd Trade Day, has launched a new cosmetics line utilizing its wellness prescription expertise. Through this initiative, the company is expanding its wellness business into immune enhancement, medical devices, and beauty, thereby strengthening its growth engines. The newly introduced “Luthione Skincare” line primarily targets the Chinese market. Daehan New Pharm has signed a supply and sales agreement with Shenzhen Neo Med Hospital Management, and with a long-term strategic perspective, plans to systematically develop and manage the market. As part of this plan, the company will export an initial shipment of 200,000 units to launch the product in China. By leveraging its successful domestic wellness marketing experience, Daehan New Pharm expects that the introduction of Luthione Skincare in China will create synergy with its existing wellness products and enhance its brand image as a leading wellness specialist.

- Daehan New Pharm Wins the “10 Million Dollar Export Tower” at the 52nd Trade Day- CEO Bae Gun-Woo Receives Commendation from the Minister of Trade, Industry and EnergyDaehan New Pharm received the “10 Million Dollar Export Tower Award” at the 52nd Trade Day ceremony. Daehan New Pharm is a mid-sized pharmaceutical company specialized in the fields of wellness and chronic disease treatment, focusing on professional pharmaceuticals, veterinary medicines, stem cell technology, and bio-process materials. Through specialization, concentration, and globalization of its core businesses, the company currently generates about 15% of its total performance from overseas markets. Unlike most domestic pharmaceutical companies that mainly export raw materials, Daehan New Pharm has built its presence through exports of finished pharmaceutical products to China, Russia, and Southeast Asia, while also pioneering new markets such as Cuba. By actively targeting emerging economies, the company has expanded its global presence to over 20 countries and nurtured partnerships with more than 60 strategic partners, successfully establishing a worldwide network. This achievement carries great significance as a growth model for mid-sized pharmaceutical firms. Global expansion has not only strengthened Daehan New Pharm’s growth momentum through overseas market development but has also elevated its overall management capabilities. The company’s commitment to global-level quality management, internationally trusted branding, and its success in challenging environments have instilled a strong spirit of challenge and confidence among employees—an invaluable asset beyond the tangible achievement of ten million dollars in exports. This organizational drive has enabled Daehan New Pharm to double its size over the past five years and build sustainable growth capabilities exceeding 20%. The company aims to increase the proportion of overseas business from 15% to over 20% by 2020, advancing beyond export-based globalization toward deeper strategic alliances and direct international expansion. In addition, CEO Bae Gun-Woo was awarded the Minister of Trade, Industry and Energy Commendation in recognition of his leadership and outstanding contribution to expanding finished pharmaceutical exports. Since his appointment in 2008, he has doubled the company’s export volume—from 5.83 million dollars to over 10 million dollars—achieving remarkable export growth and transforming Daehan New Pharm into a globally competitive pharmaceutical exporter.

Daehan New Pharm, a KOSDAQ-listed company well known for its “Luthione” and “Cindella” injection, has launched its new whitening skincare line, “Luthione Skin Care”, as part of its wellness business expansion. The newly introduced “Luthione Skin Care” is a dual-function product line that improves both whitening and wrinkle reduction. It consists of two essential base items—a lotion and a cream—with plans for further expansion of the line. Through continuous innovation in wellness and medical formulations, Daehan New Pharm has achieved remarkable results by focusing on specialization, global business expansion, and direct management of medical institutions. The company is strengthening its distribution network, diversifying its product portfolio through ongoing launches, and developing creative sales strategies by cultivating top-tier talent. The release of this cosmetic line represents the company’s initiative to apply its wellness-based pharmaceutical research expertise to cosmetics, thereby establishing a new, integrated wellness product line. One of the key ingredients in Luthione Skin Care, β-glucan, has been enhanced to achieve over 80% higher absorption compared to existing β-glucan products. Combined with glutathione and adenosine, it delivers powerful whitening and nourishing effects to the skin. As more pharmaceutical companies diversify into the cosmetics sector, Luthione Skin Care stands out for its unique formulation, clinical expertise, and proven efficacy, drawing attention as a differentiated cosmeceutical line in the market.

- Achieved 28.9% increase in sales and 24.4% increase in operating profit compared to the previous year- Confirmed receipt of the 10 Million Dollar Export Tower AwardDaehan New Pharm’s growth momentum continued through the third quarter of 2015. By the end of Q3 2015, cumulative sales reached 66.955 billion KRW, up 28.9% year-over-year, and operating profit increased by 24.4% to 7.293 billion KRW. The operating profit margin also improved to 10.9%, indicating sustained qualitative growth driven by profitability. In addition to this growth, the company reduced accounts receivable by 353 million KRW and borrowings by 1.548 billion KRW compared to the end of 2014. This led to an improvement in accounts receivable turnover days by 33.7 days and a reduction in the debt-to-sales ratio by 11.2 percentage points to 43.5%, contributing to financial stabilization. Daehan New Pharm’s strategy focuses on its mission to promote healthy lives, a happy society, and warmth by emphasizing fundamentals, strengthening core capabilities, prioritizing cash flow, proactive management, pioneering product launches, expanding distribution coverage through creative sales solutions, and talent-centered management, continuously driving value innovation. The overseas business division also recorded remarkable export growth. By developing the wellness product market in China and solidifying partnerships in Russia, the company secured the 10 Million Dollar Export Tower Award. Since beginning exports to Southeast Asia, including Vietnam, in 1999, Daehan New Pharm won the 5 Million Dollar Export Tower Award in 2007. The company exports various pharmaceuticals, including obesity treatments, to over 30 countries worldwide such as Russia, CIS countries, Vietnam, Pakistan, and Cuba. Achieving 10 million dollars in finished pharmaceutical exports reflects the internationally recognized superior quality of its products. This achievement affirms Daehan New Pharm’s position as a globally trusted pharmaceutical exporter.

The product is called “Granmectin Pellet”, a type of “Ivermectin Pellet”, developed through“Daehan New Pharm”'s advanced pellet manufacturing technology. It is designed primarily for deworming cattle and pigs, especially in pellet form for ease of administration. The core ingredient is “Ivermectin”, which effectively treats a variety of internal and external parasites in livestock. The pellet form offers advantages such as easy feeding, labor reduction, and minimal stress on animals. Besides the pellets, Daehan New Pharm also offers injectable forms like “Granmectin” and “Granmectin EF”, providing comprehensive parasitic control solutions for farmers. This product exemplifies Daehan New Pharm’s expertise in pellet manufacturing technology, ensuring high efficacy and palatability.

- Sales increased by 32.8% and operating profit increased by 34.0% compared to the same period last year- Poised to receive the 10 Million Dollar Export Tower Award- Bio division started supplying vaccines to domestic animal vaccine manufacturers from April Daehan New Pharm experienced robust growth in the first half of 2015. Cumulative sales for H1 2015 reached 44.095 billion KRW, a 32.8% increase year-over-year, while operating profit rose 34.0% to 4.820 billion KRW. The operating profit margin continued to improve, reaching 10.9%, marking a sustained 15-quarter streak of growth since Q4 2011. Alongside growth, the company reduced accounts receivable by 869 million KRW and borrowings by 598 million KRW compared to the end of 2014. This resulted in 28.3 fewer days in sales receivables turnover and a 7.9 percentage point decrease in the debt-to-sales ratio to 46.8%, indicating strengthened financial stability. Daehan New Pharm has actively implemented operational innovations such as building databases for value-based sales per clinic, disseminating successful case studies, and enhancing sales skills through role-playing. These initiatives are aimed at increasing customer value and talent development, showing positive results in parts. Exports from the overseas business division also showed remarkable growth, with H1 2015 export revenues rising 25.0% year-over-year to 6.068 billion KRW. From July 2014 to June 2015, export sales exceeded 10 million USD, ensuring receipt of the export tower award. The bio division is progressing well with its mid-to-long-term plans, having started regular vaccine supplies to domestic animal vaccine manufacturers since April. Other companies are testing Daehan New Pharm’s vaccines for productivity, safety, and cost-effectiveness to apply them in their production lines. In celebration of its 30th anniversary, Daehan New Pharm engaged its employees in reaffirming their commitment to future growth as a trusted and respected company, while concretizing visions and plans for sustainable long-term development.

Daehan New Pharm has developed the world's first natural herbal ointment containing oregano oil for the treatment of bovine mastitis. The product, named “Ecojet Ointment”, harnesses the anti-inflammatory, antioxidant, antifungal, and antiviral properties of oregano oil—whose major active ingredients, carvacrol and thymol, effectively target mastitis-causing bacteria such as Staphylococcus aureus and E. coli. Confirmed through domestic clinical trials, Ecojet Ointment reduces both pathogenic bacteria and somatic cell counts in milk, offering a patented (Patent No. 10-2015-0020676) and residue-free solution with zero withdrawal period for dairy farmers. In addition to Ecojet Ointment, Daehan New Pharm has introduced a comprehensive mastitis treatment program featuring other products like “Cephalegen” and “Synerjet”. Bovine mastitis is one of the most common diseases in dairy cattle, causing substantial economic losses through increased somatic cell counts, decreased milk quality and yield, especially prevalent during the summer season. Daehan New Pharm’s innovative herbal-based ointment provides an effective and safe alternative to antibiotics, supporting animal health and sustainable dairy production.